Thoratec downgraded to Market Perform from Outperform at Northland Securities Northland downgraded Thoratec following the CMS's announcement to initiate a National Coverage Decision analysis for VAD therapy. The firm believes there is now significant uncertainty regarding VADs and margins. Price target is $35.
News For THOR From The Last 14 Days
Check below for free stories on THOR the last two weeks.